MedTrace Logo

Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in Follicular Thyroid Tumours

NCT05052359 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2021-10-01

No results posted yet for this study

Summary

Aberration of glycosylation is a hallmark of cancer cells, and plays an important role in oncogenesis and cancer progression, including metastasis. One of the markers of aberrant glycosylation (O-linked) is the binding of the lectin Helix pomatia agglutinin (HPA), which has been demonstrated in a wide range of human cancers, especially in tumours with a more aggressive phenotype. Data on the role of HPA within follicular neoplasms of the thyroid gland are currently lacking, therefore we sought to investigate possible changes in cell surface glycosylation associated with this type of neoplasms.

Conditions

  • Follicular Thyroid Cancer

Interventions

DIAGNOSTIC_TEST

Lectin-histochemistry retrospectively performed

Lectin-histochemistry was performed on 37 archival paraffin wax-embedded specimens of various follicular thyroid tumours (10 follicular adenomas (FA), 10 minimally invasive follicular carcinomas (miFTC), 13 widely invasive follicular cancers (wiFTC) and 4 metastatic follicular thyroid cancers (metFTC)).

Sponsors & Collaborators

  • National University Health System, Singapore

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2021-08-01
Completion
2021-09-01

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05052359 on ClinicalTrials.gov